216 related articles for article (PubMed ID: 33768900)
1. Successful treatment of IgG4-related hypertrophic pachymeningitis with induction rituximab and dexamethasone followed by maintenance rituximab.
Seegobin K; Moustafa MA; Gannon N; Keller K; Hastings J; Gupta V; Tun HW; Jiang L
Clin Case Rep; 2021 Mar; 9(3):1610-1614. PubMed ID: 33768900
[TBL] [Abstract][Full Text] [Related]
2. Treatment of IgG4-related disease-associated hypertrophic pachymeningitis with intrathecal rituximab: a case report.
Balaban DT; Hutto SK; Panzarini BP; O'Shea A; Varma A; Jones PS; Chwalisz BK; Stone JH; Venna N
Front Neurol; 2023; 14():1189778. PubMed ID: 37292126
[TBL] [Abstract][Full Text] [Related]
3. Pachymeningitis associated with IgG4-related disease and ANCA positivity: Case report and review of the literature.
Gautier F; Neumann L; Adle-Biassete H; Rubenstein E; Bernat AL; Chimon A; Mouly S; Sène D; Comarmond C
Autoimmun Rev; 2023 Apr; 22(4):103285. PubMed ID: 36738953
[TBL] [Abstract][Full Text] [Related]
4. Polycystic subdural hygroma associated with immunoglobulin G4-related intracranial hypertrophic pachymeningitis: a case report.
Ota K; Nakazato Y; Okuda R; Yokoyama R; Kawasaki H; Tamura N; Yamamoto T
BMC Neurol; 2020 Jun; 20(1):228. PubMed ID: 32498716
[TBL] [Abstract][Full Text] [Related]
5. A Case of Hypertrophic Pachymeningitis Associated with Immunoglobulin-G4 and c-ANCA.
Wyrostek S; Chakrabarti S; Baldwin K; Avila JD
Case Rep Neurol; 2019; 11(3):290-294. PubMed ID: 31762760
[TBL] [Abstract][Full Text] [Related]
6. Immunoglobulin-G4-related hypertrophic pachymeningitis with antineutrophil cytoplasmatic antibodies effectively treated with rituximab.
Popkirov S; Kowalski T; Schlegel U; Skodda S
J Clin Neurosci; 2015 Jun; 22(6):1038-40. PubMed ID: 25861887
[TBL] [Abstract][Full Text] [Related]
7. [Pachymeningitis associated with IgG4 disease].
Zimelewicz Oberman D; Cuello Oderiz C; Baccanelli M; Christiansen S; Zurrú MC
Medicina (B Aires); 2017; 77(3):242-244. PubMed ID: 28643686
[TBL] [Abstract][Full Text] [Related]
8. Intrathecal rituximab in immunoglobulin G4-hypertrophic pachymeningitis.
Soares C; Martins DF; Pestana-Silva R; Honavar M; Faria O; Abreu P; Costa A
J Neuroimmunol; 2019 Sep; 334():576997. PubMed ID: 31254930
[TBL] [Abstract][Full Text] [Related]
9. Hypertrophic pachymeningitis due to IgG4-related disease (RD-IgG4). A case report.
Sergio P; Alejandro R; Cristian F
Reumatol Clin (Engl Ed); 2023; 19(6):338-344. PubMed ID: 37179159
[TBL] [Abstract][Full Text] [Related]
10. Complete remission of central nervous system manifestations of IgG4-related disease with rituximab - a case report.
Sihvonen AJ; Laakso SM; Tynninen O; Saaren-Seppälä H; Löfberg M
Ther Adv Neurol Disord; 2023; 16():17562864231186091. PubMed ID: 37483642
[TBL] [Abstract][Full Text] [Related]
11. IgG4-Related Intracranial Hypertrophic Pachymeningitis : A Case Report and Review of the Literature.
Takeuchi S; Osada H; Seno S; Nawashiro H
J Korean Neurosurg Soc; 2014 May; 55(5):300-2. PubMed ID: 25132941
[TBL] [Abstract][Full Text] [Related]
12. Rituximab for corticosteroid-resistant relapsing IgG4-related intracranial pachymeningitis: report of two cases.
Mageau A; Shor N; Fisselier M; Aboab J; Lecler A; Rebours C; Adle-Biassette H; Gout O; Deschamps R
Pract Neurol; 2018 Apr; 18(2):159-161. PubMed ID: 29208730
[TBL] [Abstract][Full Text] [Related]
13. Refractory IgG4-related disease complicated with organising pneumonia and hypertrophic pachymeningitis.
Abe F; Michishita Y; Saito M; Nara M; Wakui H; Takahashi N
Mod Rheumatol Case Rep; 2022 Jun; 6(2):278-281. PubMed ID: 35355069
[TBL] [Abstract][Full Text] [Related]
14. Immunoglobulin g4-related hypertrophic pachymeningitis with skull involvement.
Lee YS; Lee HW; Park KS; Park SH; Hwang JH
Brain Tumor Res Treat; 2014 Oct; 2(2):87-91. PubMed ID: 25408931
[TBL] [Abstract][Full Text] [Related]
15. IgG4-related intracranial hypertrophic pachymeningitis with skull hyperostosis: a case report.
Lin CK; Lai DM
BMC Surg; 2013 Sep; 13():37. PubMed ID: 24053604
[TBL] [Abstract][Full Text] [Related]
16. IgG4-related pachymeningitis-Long term follow up and outcome of six patients.
Yardimci GK; Arslan D; Babaoğlu B; Bolek EC; Kilic L; Saglam A; Tuncer A; Söylemezoğlu F; Gocmen R; Oguz KK; Tan E; Karadag O
Int J Rheum Dis; 2023 Sep; 26(9):1853-1860. PubMed ID: 37403944
[TBL] [Abstract][Full Text] [Related]
17. Clivus-involved immunoglobulin G4 related hypertrophic pachymeningitis mimicking meningioma: A case report.
Yu Y; Lv L; Yin SL; Chen C; Jiang S; Zhou PZ
World J Clin Cases; 2022 Jun; 10(18):6269-6276. PubMed ID: 35949844
[TBL] [Abstract][Full Text] [Related]
18. IgG4-related hypertrophic pachymeningitis: clinical features, diagnostic criteria, and treatment.
Lu LX; Della-Torre E; Stone JH; Clark SW
JAMA Neurol; 2014 Jun; 71(6):785-93. PubMed ID: 24733677
[TBL] [Abstract][Full Text] [Related]
19. IgG4-related disease: a rare but treatable cause of refractory intracranial hypertension.
Williams T; Marta M; Giovannoni G
Pract Neurol; 2016 Jun; 16(3):235-9. PubMed ID: 26657781
[TBL] [Abstract][Full Text] [Related]
20. Treatment of IgG4-related pachymeningitis in a patient with steroid intolerance: The role of early use of rituximab.
Gospodarev V; Câmara J; Chakravarthy V; Perry A; Wood M; Dietz R; Wang J; De Los Reyes K; Raghavan R
J Neuroimmunol; 2016 Oct; 299():62-65. PubMed ID: 27725123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
